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Abstract
Background: The presence of counterfeits and sub-standards in African medicines market is a
dramatic problem that causes many deaths each year. The increase of the phenomenon of
pharmaceutical counterfeiting is due to the rise of the illegal market and to the impossibility to
purchase branded high cost medicines.
Methods: In this paper the results of a quality control on antimalarial tablet samples purchased in
the informal market in Congo, Burundi and Angola are reported. The quality control consisted in
the assay of active substance by means of validated liquid chromatographic methods, uniformity of
mass determination, disintegration and dissolution tests. Moreover, a general evaluation on label
and packaging characteristics was performed.
Results: The results obtained on thirty antimalarial tablet samples containing chloroquine, quinine,
mefloquine, sulphadoxine and pyrimethamine showed the presence of different kinds of problems:
a general problem concerning the packaging (loose tablets, packaging without Producer name,
Producer Country and sometimes without expiry date); low content of active substance (in one
sample); different, non-declared, active substance (in one sample); sub-standard technological
properties and very low dissolution profiles (in about 50% of samples). This last property could
affect the bioavailability and bioequivalence in comparison with branded products and could be
related to the use of different excipients in formulation or bad storage conditions.
Conclusion: This paper evidences that the most common quality problem in the analysed samples
appears to be the low dissolution profile. Here it is remarked that the presence of the right active
substance in the right quantity is not a sufficient condition for a good quality drug. Dissolution test
is not less important in a quality control and often evidences in vitro possible differences in
therapeutic efficacy among drugs with the same active content. Dissolution profile can be
dramatically affected by the choice of excipients in the oral solid formulation and, in many cases, is
out of specifications due to the absence of formulation studies by producers of developing
countries.
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Background
One of the effects of poverty is that the medicines market
in developing countries consists essentially of illegal ven-
dors. The economic restrictions, the weak drug-regulatory
systems and the insufficient controls on production, dis-
tribution and importation promote a rise of the illegal
medicines market [1]. Moreover, the necessity of lowering
the treatment costs induces the diffusion in the market of
loose medicines, without the original primary packaging,
of which, in many cases, the producer name and country,
the batch number and the expiry date are not available,
thus preventing any possible control of the origin and the
quality of the drug, as recommended by the World Health
Organization (WHO) [2]. Furthermore, storage and sell-
ing conditions are inadequate: in many developing coun-
tries, drugs are maintained at high temperature and
humidity, not in the original packaging and not protected
from the sun. These conditions accelerate the drug degra-
dation process with, in some cases, a lowering of the
active substance strength and an increase of degradation
products and, possibly, of toxicity [3]. Moreover, storage
conditions in tropical regions could affect the drug release
profile, as evidenced in medicines from the Tanzanian
market [4]. The low quality (sub-standard) medicines and
the presence of counterfeits, together with a poor adher-
ence to therapy by the patient, are important causes of
death in developing countries [5,6]. In clinical trials, the
therapies are well-monitored and the medicines are of
good guaranteed quality, but the real therapeutic condi-
tions are very different. Most individuals buy cheap med-
icines in the informal/illegal market without taking into
consideration the risk of it. On the other hand, in most of
sub-Saharan countries, the patients have no choice,
because the only chance to purchase medicines, when
they exist, is through the informal market. This situation
favours the development of the illegal traffic of counter-
feits. The evaluation of counterfeit and sub-standard med-
icines in developing countries is about 25% of marketed
medicines but, in some countries, this percentage may
increase up to 60% [7]. WHO defines a counterfeit medi-
cine as one which is deliberately and fraudulently misla-
belled with respect to identity and/or source.
Counterfeiting can apply to both branded and generic
products and counterfeit products may include products
either with correct ingredients, with the wrong ingredi-
ents, without any active ingredients, with incorrect quan-
tity of active ingredients or with fake packaging [8]. In
developing countries, most counterfeit are of life-saving
medicines such as antibiotics, antimalarials, anti-tubercu-
losis and antiretroviral drugs [9-17]. Every year many
cases of counterfeit essential drugs causing therapy ineffi-
cacy, development of drug resistance and sometimes
death are reported [18-21]. Considering the WHO defini-
tion of a counterfeit medicine, how should one consider
medicines in plastic bags or enveloped in pieces of paper
without any producer name, batch number or expiry date,
being sold by non-authorized vendors? What is the real
quality of these medicines? What are the real strength, the
impurities quantity, the pharmaceutical-technological
properties and the bioavailability of these medicines?
In this paper the results of a quality control performed on
antimalarial tablets purchased by random sampling in the
illegal/informal market in the capitals of Congo, Burundi
and Angola are reported. The assay of the active sub-
stances was performed by reversed phase liquid chroma-
tography (RP-LC). The uniformity of mass determination,
the tablet disintegration and dissolution tests were also
carried out. The last was performed to obtain in vitro infor-
mation on possible bioavailability problems [22].
Methods
Medicinal samples
Commercial tablet samples of quinine, sulphadoxine and
pyrimethamine, chloroquine, mefloquine were pur-
chased from illegal vendors or in small informal pharma-
cies in Goma (Congo), Bujumbura (Burundi) and Luanda
(Angola). Different samplings were performed in different
places of these cities with the aid of local health profes-
sionals. For each sample the site of purchase, the cost, the
environmental conditions (e.g. open stall, without protec-
tion from sun, etc.), the product name, the strength, the
producer name and country (if available), the batch
number and the expiry date (if available), was recorded.
The samples were then sent by air to the Istituto Superiore
di Sanità in Italy, where analytical controls were per-
formed on thirty antimalarial tablet samples. Italian com-
mercial antimalarial tablet samples were used for
comparison in dissolution tests and in the analytical
method development and validation. Quinine 250 mg
tablets (Nova Argentia, Milano, Italy), chloroquine 250
mg tablets (Bayer AG Leverkusen, Germany), mefloquine
250 mg tablets (Roche S.p.A. Milano, Italy) were pur-
chased from the Italian national market. Sulphadoxine
and pyrimethamine (500 mg/25 mg) tablets (Roche
Pharma, Reinach, Suisse) were purchased from the Vati-
can State Pharmacy.
Chemicals
Chloroquine diphosphate salt (purity>98%), quinine sul-
phate salt USP (purity = 99.8%) and pyrimethamine
(purity>99%) used in standard preparations were pur-
chased from Sigma Chemical Company (St. Louis, MO,
USA). Mefloquine hydrochloride and sulphadoxine refer-
ence standards were obtained from the European Pharma-
copoeia (EDQM, Strasbourg, France). Potassium
dihydrogen phosphate was from ICN Biomedicals Inc.
(Ohio, USA), 85% phosphoric acid was from Friedel-de
Haen GmbH (Germany); 1-pentane-sulfonic acid sodium
salt and 99.5% triethylamine were from Sigma-AldrichMalaria Journal 2007, 6:22 http://www.malariajournal.com/content/6/1/22
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GmbH (Steinthem, Germany), HPLC-grade methanol
and acetonitrile were from Baker (Deventer, Holland). All
other reagents were of analytical grade.
Chromatographic analysis
The chromatographic equipment consisted of a Series
1100 HPLC system with an automatic injector and a
photo-diode array detector (Agilent Technologies Deut-
schland GmbH, Waldbronn, Germany). For data collec-
tion and calculation Chemstation software was used
(Agilent Technologies). For the analysis of quinine, chlo-
roquine and mefloquine tablets, a single method, previ-
ously validated, was employed [23]. Samples were
prepared by suspending the suitable quantity of powder
from tablets in phosphate buffer (for chloroquine) and in
methanol (for quinine and mefloquine) to obtain, after
centrifugation, a final concentration of 0.1 mg/ml in
active substance. Quantification of medicinal samples
was obtained in triplicate analysis by comparison with
standard solutions prepared in triplicate. The chromato-
graphic column was a Symmetry C18, 75 mm × 4.6 mm
i.d., 3.5 μm particle size (Waters Corporation, Massachus-
setts, USA) thermostated at 30°C. The detection wave-
length was 230 nm and the injection volume was 10 μl.
Mobile phase A was a buffer consisting of 50 mM potas-
sium dihydrogen phosphate, 7 mM 1-pentane-sulfonic
acid sodium salt and 0.1% v/v triethylamine. The pH was
adjusted to 2.9 ± 0.1 with phosphoric acid before bringing
to volume. Mobile phase B was acetonitrile. The elution
was a gradient delivered at 1 ml/min as follows: 0–5 min:
from 90% A to 70% A, 5–8 min: from 70% A to 50% A,
8–10 min: 50% A. The system was then re-equilibrated to
90% A.
For the analysis of sulphadoxine and pyrimetamine fixed
dose composition tablets, the method reported in the
United States Pharmacopeia, slightly modified, was
employed [24]. The method was re-validated in terms of
linearity, precision and accuracy, as reported in Table 1.
Samples were prepared by sonicating a suitable quantity
of powder from tablets in 35 ml of acetonitrile and by
adding 65 ml of 1% v/v acetic acid solution. After filtra-
tion samples were opportunely diluted with the same sol-
vent mixture to obtain a final concentration of 0.05 mg/
ml and 0.125 mg/ml in sulphadoxine and pyrimeth-
amine, respectively. Quantification of medicinal samples
was obtained in triplicate by comparison with standard
solutions prepared in triplicate at the test concentration.
The chromatographic column for sulphadoxine and
pyrimethamine analyses was a C18 Supelcosil ABZ+Plus,
250 mm × 4.6 mm i.d., 5 μm particle size (Supelco, Belle-
fonte, USA) thermostated at 25°C. The detection wave-
length was 254 nm and the injection volume was 10 μl.
Mobile phase was a mixture of 1% v/v acetic acid: ace-
tonitrile (64:36 v/v) delivered at 1 ml/min.
Other quality control tests
The Uniformity of Mass was determined on each sample
according to the European Pharmacopoeia [25]. Disinte-
gration test was performed following the method and lim-
its reported in the European Pharmacopoeia [26] by using
a PTZ AUTO disintegration apparatus (Pharma Test Appa-
ratebau GmbH, Hainburg, Germany). Six tablets of each
sample were placed inside the disintegration apparatus
filled with distilled water at 37°C and the disintegration
was verified after 15 minutes. For sugar coated tablets dis-
integration was verified after 60 minutes as indicated in
the European Pharmacopoeia. Dissolution Test was per-
formed following the specific methods described in the
United States Pharmacopoeia [24] by using an AT7 Smart
dissolution apparatus (Sotax Italia, Milano, Italy) con-
nected with a Lambda 26 spectrophotometer (Perk-
inElmer, Wellesley, USA). For quinine tablets a
dissolution medium consisting of 0.1N hydrochloric acid
was employed, for chloroquine the medium was distilled
water and for sulphadoxine and pyrimethamine tablets
phosphate buffer at pH = 6.8 was used. The dissolution
profiles for chloroquine and quinine were obtained by
Table 1: Validation data of the LC method for sulphadoxine and pyrimethamine tablets analysis.
Linearity Sulphadoxine Pyrimethamine
Range 10–200% 10–200%
Equation Y = 26873 X - 3 Y = 19603 X + 2
r2 0.99998 0.99994
Intra-day Precision
MEANn = 6 (%RSD) 97.2% (0.6) 101.1% (0.5)
MEANn = 6 (%RSD) 96.8% (0.4) 102.9% (0.4)
MEANn = 6 (%RSD) 98.0% (1.5) 103.9% (0.7)
Inter-day Precision
MEANn = 3 (%RSD) 97.3% (0.6) 102.6% (1.4)
Accuracy
Linear equation (measured % vs added %) Y = 1.05 X + 97.9 Y = 1.01 X + 100.7
r2 0.998 0.99994Malaria Journal 2007, 6:22 http://www.malariajournal.com/content/6/1/22
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measuring the absorbance at 343 nm and 248 nm, respec-
tively. For sulphadoxine and pyrimethamine the dissolu-
tion profiles were obtained by LC assay.
Results and Discussion
Information about the vendor, the price and the storage
conditions were obtained from the filled in form attached
to each sample. In more than 50% of cases, the medicines
were sold loose, without the original primary packaging,
into little plastic bags with the name of the active ingredi-
ent, the strength, the expiry date and, only in some cases,
the producer name and country written by pen. In 25% of
the analysed samples the expiry date was not available.
Moreover, the storage conditions reported in the form
were inadequate (open stall, without protection from sun,
hand bags).
The cost of twenty tablets was about 1–4 USD (United
States Dollars) for quinine, 0.2–2 USD for chloroquine,
9–15 USD for mefloquine and 1.5–3 USD for sulphadox-
ine and pyrimethamine fixed dose composition. In gen-
eral, from data reported in each form, it was observed that
the price of medicines in small pharmacies is not higher
than that in the illegal market; on the contrary, sometimes
the illegal market sells the same drug at higher price. On
the other hand, it should be considered that the so called
"small pharmacies" are not, in many cases, legally recog-
nized. Moreover, in both cases no difference in the prob-
ability to buy a sample constituted by either loose tablets
or tablets packaged in the original blister was found. Con-
cerning the countries of origin, Indian and local products
are the more represented in the informal market. Interest-
ing is the case of sample named Qc1, Quinine from the
Congo market: this medicine was illegally sold, being a
not saleable sample of the "Essential Drugs Programme-
WHO", coming from an International Cooperation pro-
gramme. This event is not infrequent: in many developing
countries a percentage of food and drugs donated by
International Cooperation reaches the illegal market. An
other interesting specimen was the sample named SPc19,
sulphadoxine and pyrimethamine tablets produced in
China and purchased from Congo: the absence of the
expiry date on blister and other characteristics, as the pro-
ducer name that was similar, but not identical, to that of
a real Chinese producer, induced to consider this sample
as a counterfeit. The samples were analysed to evaluate
their quality. The assay of active substance was performed
by validated HPLC methods. Moreover, the uniformity of
mass and the disintegration performances were evaluated.
Finally, the dissolution profiles were evaluated to obtain
some information about possible bioavailability and
bioequivalence problems with respect to some commer-
cial European products. In Table 2 the results obtained for
each sample are reported. The samples were considered
"in specifications" (IS) when the assay for the active sub-
stance was in the 90–110% range, based on the larger
specifications among those reported in the US, British,
European and International Pharmacopeias [24,27-29].
The assay on the active substance evidenced that one sam-
ple of quinine (Qc17) was out of specifications (OOS)
with a lower amount of active substance (88.6%) and in
an other case the active substance found was different
from that declared (sample Qb5). The chromatographic
retention time (R.T.) of the peak and the UV absorption
spectrum allowed to establish that the active was chloro-
quine instead of quinine. The use of the same analytical
method to analyse both kind of samples allowed an easy
identification of the wrong ingredient. Moreover, the
quantity of active compound was also found different
from the one declared (82.4%). This is a typical example
of counterfeit medicine characterized by wrong active and
wrong quantity. Moreover, considering the different anti-
malarial efficacy of these two actives and considering that
in Burundi, where this counterfeit medicine was pur-
chased, the more common form of malaria is caused by
chloroquine-resistant Plasmodium falciparum, dispensing
this medicine to a patient can give rise to inefficacy and
even to death. Figure 1 reports the chromatographic pro-
files and the absorption spectra of quinine sample Qb5
purchased in the informal market in Burundi (A), stand-
ard quinine sulphate (B) and standard chloroquine
diphosphate (C). The different R.T. (4.5 instead of 4.9
minutes), the UV spectra and the absence of the two char-
acteristic impurities at R.T. 4.45 and 5.35 minutes, clearly
indicate that the sample was not quinine. After the identi-
fication of the real active substance, the extraction was
repeated to evaluate the quantity of chloroquine in the
tablet. The strength was about 250 mg, characteristic of
chloroquine tablets, instead of 300 mg, as declared. The
substitution of quinine with the cheaper chloroquine
appears to be an usual practice in African countries as
reported also by other authors [21]. Concerning the uni-
formity of mass, two samples were found OOS. Disinte-
gration performances for all samples were found IS, as
reported in Table 2.
Dissolution was performed to obtain information about
the possible differences in the bioavailability of the anti-
malarial samples. For quinine sulphate and chloroquine
phosphate tablets dissolution specification was above
75%(Q) (equivalent to "not less than 80%") of the
labelled amount should be dissolved in 45 minutes; for
sulphadoxine and pyrimethamine tablets dissolution
specification was above 60%(Q) (equivalent to "not less
than 65%") of the labelled amount should be dissolved in
30 minutes, as reported in the US Pharmacopeia specific
monographs [24]. The results of the dissolution tests are
reported in Table 2 and representative dissolution profiles
are shown in Figure 2 and Figure 3. For some quinine tab-
lets an immediate complete dissolution was observedMalaria Journal 2007, 6:22 http://www.malariajournal.com/content/6/1/22
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Chromatographic profiles of tablets sample Qb5, purchased as quinine, 300 mg, from Burundi (A), of quinine sulphate standard  (B) and of chloroquine diphosphate standard (C) Figure 1
Chromatographic profiles of tablets sample Qb5, purchased as quinine, 300 mg, from Burundi (A), of quinine sulphate standard 
(B) and of chloroquine diphosphate standard (C). The retention time and the UV-absorption spectrum recorded in the peak 
apex (reported in the inset), clearly indicates that the sample is chloroquine.
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(curve a, Figure 2A) while, for other samples, sigmoidal
and biphasic behaviour was found (curves c, e, f and g,
Figure 2A). Four samples were found OOS, as reported in
Table 2. For chloroquine tablets, three very different
biphasic behaviours, all OOS, were observed. It should be
recalled that the sample Qb5, reported here in the chloro-
quine dissolution profiles (curve b, Figure 2B), had been
sold as quinine. Moreover, sample Ca1, that was IS for the
assay, showed a very poor dissolution profile (curve c, Fig-
ure 2B). For sulphadoxine two samples were OOS but, in
general, more regular trends were observed, as indicated
in Figure 3A (curves g and f). The same samples analysed
for dissolution profile of pyrimethamine evidenced very
low percentages of active substance dissolved: six out of
Table 2: Analytical results of the antimalarial samples purchased from the informal market in Congo, Burundi and Angola.
Sample1 Packaging/Exp. Date2 Origin3 % Assay (%RSD) Uniformity of 
Mass
Disintegration 
Test
% Dissolved4 
(%RSD)
Qc1 In the "Essential Drugs Programme-WHO" pot/02-2007 Cyprus 97.0 (0.9) IS IS 98 (1)
Qc4 loose tablets/08-2008 Congo 99.8 (0.4) IS IS 96 (1)
Qc6 loose tablets/07-2007 Holland 102.7 (0.7) IS IS 100 (2)
Qc10 loose tablets/04-2008 Congo 100.3 (0.8) IS IS 96 (2)
Qc11 loose tablets/10-2007 Congo 99.5 (0.7) OOS IS 96 (1)
Qc12 loose tablets/08-2006 Congo 98.5 (0.2) IS IS 101 (1)
Qc14 loose tablets/NA NA4 96 (2) IS IS 75 (5) OOS
Qc17 loose tablets/NA NA 88.6 (0.6) OOS IS IS 58 (7) OOS
Qc18 loose tablets/NA NA 97.4 (0.8) IS IS 72.3 (0.6) OOS
Qc20 in blister/01-2007 India 95.2 (0.4) IS IS 99 (4)
Qb1 loose tablets/11-2009 NA 99.0 (0.5) IS IS 96 (1)
Qb4 in blister/05-2008 Burundi 99 (1) IS IS 101 (2)
Qb5 loose tablets/05-2008 NA Different Active OOS IS 30 (8) OOS
Qb6 loose tablets/03-2008 NA 95.9 (0.3) IS IS 88 (4)
Qa3 in blister and secondary packaging/08-2008 India 97.4 (0.8) IS IS 50 (5) OOS
Qa5 in blister/10-2007 India 98 (1) IS IS 98 (2)
Ma4 in blister/06-2006 Brazil 102.6 (0.9) IS IS Not evaluated
Ma6 in blister and secondary packaging/08-2007 Cyprus 102.4 (0.8) Not evaluated Not evaluated Not evaluated
Ca1 in blister and secondary packaging/08-2007 India 102 (2) IS IS 26 (3) OOS
Ca2 in blister/08-2007 India 102.8 (0.7) IS IS 75 (7) OOS
% Dissolved5 
(%RSD)
SPc2 tablets loose/11-2006 Malta S = 94.8 (0.6) IS IS S = 79.5 (0.2)
P = 99.1 (0.1) P = 73 (2)
SPc3 in blister and secondary packaging/06-2007 India S = 96.3 (0.3) IS IS S = 97 (5)
P = 100.3 (0.2) P = 67.9 (0.6)
SPc5 in blister and secondary packaging/02-2007 India S = 98 (1) IS IS S = 99 (1)
P = 100.9 (0.6) P = 72 (1)
SPc7 tablets loose/10-2008 Cyprus S = 95.9 (0.6) IS IS S = 95 (3)
P = 97.9 (0.4) P = 73 (3)
SPc8 tablets loose/NA NA S = 94.0 (0.2) IS IS S = 57 (3) OOS
P = 94.1 (0.6) P = 24 (1) OOS
SPc9 in blister and secondary packaging/06-2007 India S = 96 (1) IS IS S = 84 (3)
P = 102.7 (0.1) P = 52 (2) OOS
SPc13 loose tablets/NA NA S = 93.3 (0.4) IS IS S = 80.6 (0.7)
P = 104.6 (0.6) P = 53 (7) OOS
SPc15 loose tablets/NA NA S = 95 (1) IS IS S = 72 (1)
P = 100.7 (0.9) P = 45 (3) OOS
SPc16 loose tablets/NA NA S = 97.3 (0.2) IS IS S = 95 (1)
P = 100.8 (0.5) P = 55 (5)OOS
SPc19 in blister/NA China S = 93.8 (0.4) IS IS S = 47 (2)OOS
P = 99.1 (0.8) P = 18.6 (0.6)OOS
1Qc#, Qb#, Qa#: Quinine tablet samples from Congo, Burundi and Angola, respectively
Ca#: Chloroquine tablet samples from Angola
Ma#: Mefloquine tablet samples from Angola
SPc#: Sulphadoxine and pyrimethamine tablet samples from Congo
2 The samples were purchased in August 2005
3 Declared Producer Origin Country
4 USP tolerances for quinine sulphate and chloroquine phosphate tablets: not less than 75%(Q) (equivalent to "not less than 80%") of the labelled 
amount is dissolved in 45 minutes.
5 USP tolerances for sulphadoxine and pyrimethamine tablets: not less than 60%(Q) (equivalent to "not less than 65%") of the labelled amount is 
dissolved in 30 minutes.
NA: not available
IS: in specifications
OOS: out of specificationsMalaria Journal 2007, 6:22 http://www.malariajournal.com/content/6/1/22
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ten samples were found OOS (curves b-g, Figure 3B) and
two of them with a very low release percentage (24% and
19% dissolved after 30 minutes). Pyrimethamine is prac-
tically insoluble in water [26] and this characteristic dra-
matically affects the dissolution profile, as often observed
for slightly soluble or insoluble active substances. These
results led to the hypothesis that a problem in the bioa-
vailability may be due to the formulations employed and/
or to the storage conditions [4]. In fact, in local products
or in products obtained from other developing Countries,
the excipients in the formulation of branded products are
often substituted by cheaper ones without previously per-
forming bioavailability or bioequivalence studies or, at
least, comparative in vitro studies to verify the influence of
the different formulation on the dissolution profile.
Moreover, the possible existence of polymorphic forms of
the active could also affect the bioavailability of the for-
mulation as well as its dissolution profile.
Conclusion
The results obtained from the analysed samples show
three different kinds of problems: (i) the presence of a low
quantity of active substance, observed in one sample; (ii)
the substitution of an active substance by a different one,
observed in one sample, and (iii) the OOS results con-
cerning the dissolution profile, a parameter that correlates
with bioavailability. This kind of OOS was observed in 13
samples out of 28 (46% of cases). Moreover, the high
RSD% values observed in some dissolution tests indicate
a large variability in the production process, that is non-
controlled and non-"Good Manufacturing Practices". The
dissolution test is a technological test not usually per-
formed in the quality control of samples from developing
countries market. The results reported here indicate that
in many cases even samples containing the right quantity
of active substance could do not show the same therapeu-
tic properties in terms of bioavailability. In fact, assuming
a medicine with a very high or very low absorption rate in
the body in comparison with the branded medicine for
which in vivo efficacy was demonstrated, could affect the
good result of therapy. The change in excipients could dra-
matically affect the in vivo efficacy if a bioequivalence
study or, at least, an in vitro study such as the dissolution
test was not performed. Moreover, the OOS results were
obtained for pyrimethamine probably because of its poor
solubility in water. This argument will be investigated for
other life-saving medicines containing low water-soluble
active substances marketed in developing countries. Gen-
erally, counterfeits and sub-standards are considered an
economic and health problem mainly owing to lower
strength, absence of active substance or presence of a dif-
ferent active. The results here reported evidenced as the
legal or illegal production in developing countries could
also involve problems of bioavailability and bioequiva-
lence of medicinal products. When bioequivalence stud-
ies are not performed, the assumption that a drug with the
right content of active substance is "in standard" is not
always correct, especially with low soluble actives. In these
cases, the health professional should consider that the
therapeutic response could be very different from that
expected.
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Dissolution profiles of representative samples of quinine (A) and chloroquine (B) tablets Figure 2
Dissolution profiles of representative samples of quinine (A) and chloroquine (B) tablets. 2A: samples Qc12 (a), Qa5 (b), Qc11 
(c), Qb6 (d), Qc18 (e), Qc17 (f), Qa3 (g); 2B: samples Ca2 (a), Qb5 (b), Ca1 (c).
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Dissolution profiles of representative samples of sulphadoxine (A) and pyrimethamine (B) fixed dose composition tablets Figure 3
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